share_log

上海医药:注射用头孢唑肟钠通过仿制药一致性评价

SH PHARMA: The injectable Cefoperazone Sodium has passed the consistency evaluation for generic drugs.

Breakings ·  Mar 17 09:10

SH PHARMA announced that its holding subsidiary, Shanghai Sh pharma Xinya Pharmaceutical Co., Ltd., received the "Drug Supplement Application Approval Notice" issued by the National Medical Products Administration regarding injectable Cefoperazone Sodium, and this product has passed the consistency evaluation for generic drugs. Injectable Cefoperazone Sodium is primarily used for lower respiratory tract infections, urinary tract infections, abdominal infections, pelvic infections, sepsis, skin and soft tissue infections, bone and joint infections, meningitis caused by Streptococcus pneumoniae or Haemophilus influenzae, and uncomplicated gonorrhea caused by sensitive bacteria. In September 2023, Sh pharma Xinya applied for and received acceptance from the National Medical Products Administration for the consistency evaluation of this drug. As of the date of this announcement, the company has invested approximately 5 million yuan in research and development expenses for the consistency evaluation of this drug. In 2024, the procurement amount for this injectable drug in hospitals is 3,608.77 million yuan.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Comment Comment · Views 303

Recommended

Write a comment

Statement

This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.